Lidocaine Grindeks

Lidocaine, the active ingredient in Lidocaine Grindeks, is a local anesthetic presented as a sterile injectable solution for epidural, intramuscular, or intravenous use. It provides rapid onset of reversible nerve block for surgical, diagnostic and analgesic procedures in adult patients and is indicated for local anesthesia during these interventions.

GNH USA supplies Lidocaine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution sourced from the European Union market.

Lidocaine Grindeks is used as a local anesthetic to block nerve conduction during various procedures.

Surgical procedures: provides rapid, reversible loss of sensation at the targeted site. Diagnostic procedures: enables pain‑free examination of tissues. Labor and delivery: offers epidural analgesia for maternal comfort. Post‑operative pain control: supplies intravenous analgesia to manage acute pain.

Adverse reactions to Lidocaine Grindeks may vary in frequency and severity.

Common Side Effects: - Tingling or numbness at the injection site. - Mild hypotension or dizziness. - Nausea or metallic taste. - Transient visual disturbances.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Cardiac arrhythmias or conduction block. - Central nervous system toxicity such as seizures.

When using Lidocaine Grindeks, consider the following precautions.

Assess cardiac status: monitor heart rate and rhythm during and after administration. Evaluate hepatic function: adjust use in patients with significant liver impairment. Use caution in seizure disorders: avoid high plasma concentrations. Avoid concurrent local anesthetics: reduce risk of cumulative toxicity. Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine Grindeks may interact with other medicines; review the following.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may cause severe cardiotoxicity. - Beta‑blockers (e.g., propranolol): increase risk of bradycardia and hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise plasma lidocaine levels.

Moderate Interactions (Monitor Closely): - Inhalational anesthetics (e.g., halothane): additive CNS depression. - Diuretics (e.g., furosemide): may enhance hypotensive effect. - Opioids (e.g., morphine): increase sedation and respiratory depression.